scholarly journals Comparison of liver biopsy and non-invasive APRI test in assessing the stage of liver fibrosis in patients with chronic HCV infection

2017 ◽  
Vol 2 (5) ◽  
pp. 194
Author(s):  
Nina Adzic ◽  
Mirjana Arapovic
Keyword(s):  
Liver Fibrosis ◽  
Liver Biopsy ◽  
Hcv Infection ◽  
Non Invasive ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

scholarly journals Non-invasive methods for the diagnosis of liver fibrosis in chronic HCV infection

2019 ◽  
Vol 17 (8) ◽  
pp. 44-47
Author(s):  
A. I. Fazulzyanova ◽  
◽  
S. V. Tkacheva ◽  
A. K. Khusainova ◽  
N. F. Gayfutdinov ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Hcv Infection ◽  
Non Invasive ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

Non-invasive diagnosis of liver fibrosis progression by a clinical and US-doppler predictive model during chronic HCV infection

2003 ◽  
Vol 38 ◽  
pp. 155-156
Author(s):  
K. Mattiello ◽  
A. Favaro ◽  
E. Bernardinello ◽  
L. Cavalletto ◽  
I. Mezzocolli ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Predictive Model ◽  
Hcv Infection ◽  
Non Invasive ◽  
Fibrosis Progression ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

scholarly journals Liver Biopsies for Chronic Hepatitis C: Should Nonultrasound-Guided Biopsies Be Abandoned?

2009 ◽  
Vol 23 (6) ◽  
pp. 425-430 ◽  
Author(s):  
Jennifer A Flemming ◽  
David J Hurlbut ◽  
Ben Mussari ◽  
Lawrence C Hookey
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Biopsy ◽  
Chronic Hepatitis C ◽  
Hcv Infection ◽  
Significant Difference ◽  
The Us ◽  
Chronic Hcv Infection ◽  
Liver Biopsies ◽  
Chronic Hcv

BACKGROUND/OBJECTIVE: Liver biopsy has been the gold standard for grading and staging chronic hepatitis C virus (HCV)-mediated liver injury. Traditionally, this has been performed by trained practitioners using a nonimage-guided percutaneous technique at the bedside. Recent literature suggests an expanding role for radiologists in obtaining biopsies using an ultrasound (US)-guided technique. The present study was undertaken study to determine if the two techniques produced liver biopsy specimens of similar quality and hypothesized that at our institution, non-US-guided percutaneous liver biopsies for HCV would be of higher quality than US-guided specimens.METHODS: Liver biopsies from 100 patients with chronic HCV infection (50 consecutive US-guided and 50 consecutive non-US-guided), were retrospectively identified using a hospital histopathology database. All original biopsy slides were coded and prospectively reanalyzed by a single hepatopathologist who was blinded to the technique used in obtaining the biopsy. Additionally, all liver biopsies for chronic HCV infection completed at the centre from 1998 to 2007 were identified and the technique used was recorded. Biopsy quality was determined primarily by the number of complete portal tracts (CPTs) identifiable in the slides. The total length of specimen and the degree of fragmentation were secondary outcome measures.RESULTS: There was a slight difference observed between the US-guided and non-US-guided groups in mean age (46.3 years versus 42.5 years, repectively; P=0.018) but no differences in sex, presence of cirrhosis, bilirubin, creatinine, international normalized ratio, and grade or stage of disease. Biopsies obtained using the US-guided technique produced higher quality specimens than the non-US-guided technique based on our primary outcome of number of CPTs in the biopsy (11.8 versus 7.4; P<0.001). US-guided specimens also were longer (24.4 mm versus 19.7 mm; P=0.001), had less fragmentation (P=0.016), and a higher overall histopathological quality assessment (P=0.026) than the non-US-guided biopsies. However, there was no significant difference between the two groups in the ability to grade and stage the disease (96% US-guided versus 90% in non-US-guided (P=0.20). Over a 10-year period, 763 biopsies for chronic HCV infection were identified with an obvious trend toward the increased use of US-guided technique observed at 2% in 1998 to 85% in 2007.CONCLUSIONS: US-guided liver biopsies for chronic HCV are the most common method of obtaining specimens at the Kingston General Hospital, Kingston, Ontario, and are of higher quality than non-US-guided specimens. However, there is no significant difference in the two techniques in the ability to grade and stage chronic HCV.

Predictors of Liver Fibrosis in Patients with Chronic HCV Infection

2012 ◽  
Vol 32 (6) ◽  
pp. 1522-1529 ◽  
Author(s):  
Bahadır CEYLAN ◽  
Cem YARDIMCI ◽  
Muzaffer FİNCANCI ◽  
Ümit TÖZALGAN ◽  
Gülhan EREN ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Hcv Infection ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

scholarly journals Incidence and Predictors of Advanced Liver Fibrosis by a Validated Serum Biomarker in Liver Transplant Recipients

2017 ◽  
Vol 2017 ◽  
pp. 1-8
Author(s):  
Mamatha Bhat ◽  
Kathleen C. Rollet-Kurhajec ◽  
Aparna Bhat ◽  
Amanda Farag ◽  
Marc Deschenes ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Liver Transplant ◽  
Hcv Infection ◽  
Serum Biomarker ◽  
Advanced Fibrosis ◽  
Advanced Liver Fibrosis ◽  
Chronic Hcv Infection ◽  
Chronic Hcv ◽  
Liver Transplant Recipients

Background and Aims. Serum fibrosis biomarkers have shown good accuracy in the liver transplant (LT) population. We employed a simple serum biomarker to elucidate incidence and predictors of advanced fibrosis after LT over a long follow-up period.Methods. We included 440 consecutive patients who underwent LT between 1991 and 2013. Advanced liver fibrosis was defined as FIB-4 > 3.25 beyond 12 months after LT.Results. Over 2030.5 person-years (PY) of follow-up, 189 (43%) developed FIB-4 > 3.25, accounting for an incidence of 9.3/100 PY (95% confidence interval [CI], 8.1–10.7). Advanced fibrosis was predicted by chronic HCV infection (adjusted hazard ratio (aHR) = 3.96, 95% CI 2.92–5.36,p< 0.001), hypoalbuminemia (aHR = 2.31, 95% CI 1.72–3.09;p< 0.001), and hyponatremia (aHR = 1.48, 95% CI 1.09–2.01;p= 0.01). LT recipients with more than 1 predictor had a higher incidence of advanced fibrosis, the highest being when all 3 predictors coexisted (log-rank:p< 0.001).Conclusions. Chronic HCV infection, hypoalbuminemia, and hyponatremia predict progression to advanced liver fibrosis following LT. Patients with these risk factors should be serially monitored using noninvasive fibrosis biomarkers and prioritized for interventions.

Sign in / Sign up

Export Citation Format

Share Document